Alan Auerbach was born in United States. Alan Auerbach has scored two big successes in the risky biotech sector. Johnson & Johnson paid about $1 billion in cash in 2009 for his first cancer drug company, Cougar Biotechnology; he netted an estimated $50 million in that transaction. Shares of his latest business, Puma Biotechnology, soared in mid 2014 following good news from a late stage clinical trial of breast cancer drug neratinib, which Puma had licensed from Pfizer. Auerbach, who got through college on a mix of scholarships, fellowships and working part-time jobs, has a bachelors and a master's degree in biomedical engineering. He started his career as a research analyst covering biotech companies from Los Angeles, where Puma Biotechnology is based.
Alan Auerbach is a member of Medicine